(Q43708599)

26 November 2017

Population pharmacokinetics of continuous infusion ceftazidime (English)

1 reference

26 November 2017

1 reference

B C Frame

1

1 reference

26 November 2017

B F Facca

series ordinal

2

1 reference

26 November 2017

D P Nicolau

series ordinal

3

1 reference

26 November 2017

S N Triesenberg

series ordinal

4

1 reference

26 November 2017

1 October 1999

1 reference

Clinical Pharmacokinetics

26 November 2017

1 reference

26 November 2017

37

1 reference

26 November 2017

4

1 reference

26 November 2017

343-350

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-199937040-00005

26 November 2017

0 references

cites work

Influence of age on the pharmacokinetics of ceftazidime in acutely ill, adult patients

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in patients with renal insufficiency

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in normal and uremic subjects

1 reference

12 December 2020

Safety and pharmacokinetics of ceftazidime in patients with chronic hepatic dysfunction

1 reference

12 December 2020

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections

1 reference

12 December 2020

Measured versus estimated creatinine clearance in patients with low serum creatinine values

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

1 reference

12 December 2020

Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections

1 reference

12 December 2020

Ceftazidime and renal function

1 reference

12 December 2020

Advancing age and acute infection influence the kinetics of ceftazidime

1 reference

12 December 2020

The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy

1 reference

12 December 2020

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model

1 reference

12 December 2020

Ceftazidime in cystic fibrosis: pharmacokinetics and therapeutic response

1 reference

12 December 2020

Comparative bactericidal activity of ceftazidime against isolates of Pseudomonas aeruginosa as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method.

1 reference

12 December 2020

Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime

1 reference

12 December 2020

The importance of modeling interoccasion variability in population pharmacokinetic analyses

1 reference

12 December 2020

Killing and regrowth of bacteria in vitro: a review.

1 reference

12 December 2020

Multiple-dose pharmacokinetics of ceftazidime in cancer patients

1 reference

12 December 2020

The pharmacokinetics of ceftazidime in normal and impaired renal function

1 reference

12 December 2020

Population pharmacokinetics of ceftizoxime administered by continuous infusion in clinically ill adult patients

1 reference

12 December 2020

Intermittent bolus dosing of ceftazidime in critically ill patients.

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in male and female volunteers

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of ceftazidime in infected patients with varying degrees of renal function

1 reference

12 December 2020

Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy

1 reference

12 December 2020

Pharmacokinetics and tissue concentrations of ceftazidime in burn patients

1 reference

12 December 2020

Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime

1 reference

12 December 2020

Estimating creatinine clearance in elderly patients with low serum creatinine concentrations.

1 reference

12 December 2020

Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis

1 reference

12 December 2020

Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males

1 reference

12 December 2020

Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis

1 reference

12 December 2020

Ceftazidime: pharmacokinetics in patients and effects on the renal function

1 reference

12 December 2020

Multiple dose pharmacokinetics and therapeutic results with ceftazidime

1 reference

12 December 2020

Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

1 reference

12 December 2020

Effect of decreased renal function on the pharmacokinetics of ceftazidime

1 reference

12 December 2020

10.2165/00003088-199937040-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

26 November 2017

0 references

1 reference